Delivery Order SPE2DB22D2206-SPE2DB25FJF03
- Not listed
- The Defense Logistics Agency awarded a $21,873.30 delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Injectafer 750 mg/15 ml vials. This firm fixed-price, competitively awarded contract is scheduled for completion by August 11, 2025, with performance based in Conshohocken, Pennsylvania. The award represents a non-set-aside procurement, indicating AmerisourceBergen competed against other vendors to secure this pharmaceutical supply delivery. This delivery order...
- The Defense Logistics Agency awarded a delivery order valued at $12,066.50 to AmerisourceBergen Drug Corp for the supply of Injectafer 750 mg/15 ml vials. This competitive award, issued on August 8, 2025, with an ultimate completion date of August 11, 2025, represents a firm fixed price delivery order with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $7,239.00 to AmerisourceBergen Drug Corp for the supply of Injectafer 750 mg/15 ml vials. This firm fixed-price delivery order was competitively awarded without a set-aside designation and is scheduled for completion by July 25, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this work at its corporate office location. The delivery order represents...
- The Defense Logistics Agency (DLA) awarded a firm-fixed-price delivery order contract valued at $5,499.85 to AmerisourceBergen Drug Corporation's Corporate Office division. The contract is for the supply of 4,565,520,349 units of the pharmaceutical product Injectafer, a 750 mg/15 mL vial. This order is part of a larger Indefinite Delivery Contract (IDC) valued up to $999,999,999 through December 2025, under which AmerisourceBergen provides a comprehensive range of medical commodities to...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Injectafer 750 mg/15 ml vials on April 22, 2025, with a ceiling value of $13,894.13 and an ultimate completion date of April 23, 2025. This competitive award, which carries no set-aside designation, is issued under a firm fixed-price contract type. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, performed the work at its corporate...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $5,475.68 to AmerisourceBergen Drug Corp for the supply of Injectafer 750 mg/15 ml vials. This firm fixed-price contract, awarded on August 25, 2025, with an ultimate completion date of August 26, 2025, represents a routine pharmaceutical procurement to support federal medical supply needs. The contract is not set-aside and will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. As a...
- The Defense Logistics Agency awarded a $19,061.62 firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Injectafer 750 mg/15 mL vials. This non-set-aside contract, with a completion date of August 26, 2025, will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger pharmaceutical prime vendor vehicle with DLA, reflecting the agency's...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency on September 19, 2025, for the supply of Injectafer 750 mg/15 ml vials. The contract has a ceiling value of $10,756.00 and is structured as a firm fixed price delivery order with an ultimate completion date of September 22, 2025. This award was not issued under any set-aside program and was competitively awarded. This delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $17,360.20 to AmerisourceBergen Drug Corp for the supply of Injectafer 750 mg/15 ml vials. This non-set-aside contract, awarded on August 21, 2025, with a completion date of August 22, 2025, represents a firm fixed-price delivery order under AmerisourceBergen's larger pharmaceutical supply agreement with DLA. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania. This delivery...
- This is a firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a subsidiary of the global pharmaceutical distribution company AmerisourceBergen Corporation. The $11,001.13 award is for the supply of Injectafer 750 mg/15 ml vials, a specialty pharmaceutical product, with a completion date of March 27, 2024. AmerisourceBergen Drug Corp holds an Indefinite Delivery Contract (IDC) with DLA, valued at up to $999,999,999.00...
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB25FJF03Delivery Order
The Defense Logistics Agency awarded a $21,388.70 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Injectafer 750 mg/15 mL vials on August 1, 2025, with an ultimate completion date of August 4, 2025. This non-set-aside contract represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion vehicle that runs through December 2026. The order will be fulfilled from the vendor's Conshohocken, Pennsylvania location, where AmerisourceBergen maintains its corporate headquarters and serves as a critical pharmaceutical distributor for federal medical procurement. This delivery order is part of AmerisourceBergen's extensive portfolio supporting the Defense Health Agency and military healthcare systems worldwide. As a major pharmaceutical and healthcare solutions provider, AmerisourceBergen supplies a comprehensive range of medications and medical supplies through its DLA contract vehicle, including specialty pharmaceuticals, brand-name and generic drugs, vaccines, and medical devices across multiple therapeutic domains. The competitively awarded IDC structure allows the company to respond flexibly to federal medical supply requirements, with DLA planning to establish the next generation of Pharmaceutical Prime Vendor Global Program contracts that will involve multiple regional awards across different contractors.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $21.4k | 8/1/25 |